Loading clinical trials...

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE4

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease : EMINENT-CD

NCT07292012•Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives

View on ClinicalTrials.gov

Summary

Efficacy of Mirikizumab to achieve transmural healing in patients with Crohn's Disease

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with CD
•≥ 18 to ≤ 75 years-old
•Symptomatic CD according to PRO-2 (stool \> 3 or abdominal pain score \> 1)
•Transmural inflammation on baseline MRI (C-score \> 0.5 in at least one segment)

Exclusion Criteria

•Prior exposure to anti-p19 biological therapy
•Exposure to more than 1 class of advanced therapies at a dose approved for the treatment of Crohn's disease (janus kinase \[JAK\] inhibitors, infliximab, adalimumab, certolizumab pegol, vedolizumab, ustekinumab, or approved biosimilars for these agents
•Exclude any previous use of p19 IL23s agents
•Contra-indication to mirikizumab
•Definitive ostomy
•Colectomy with IPAA
•Isolated or uncontrolled perianal lesions
•Severe obstructive symptoms
•Intra-abdominal abscess
•Contra-indication to MRI
+6 more criteria

Locations (6)

CHU de Brest - Hôpital de la Cavale Blanche

Brest, France

CHU de Clermont Ferrand - Hôpital d'Estaing

Clermont-Ferrand, France

CHU de Nîmes Carémeau

Nîmes, France

Institut Mutualiste Monsouris

Paris, France

CHU de Toulouse - Hôpital Rangueil

Toulouse, France

CH de Valence

Valence, France

Key Dates

Start Date

January 1, 2026

Primary Completion Date

July 1, 2027

Completion Date

January 1, 2029

Last Updated

December 18, 2025

Enrollment

110

ESTIMATED participants

Conditions

Crohn Disease (CD)

Interventions

Mirikizumab - IV

DRUG

Mirikizumab - SC

DRUG

Contacts

Charlotte MAILHAT

CONTACT

+33 9 72 57 61 60 cmailhat@getaid.org

Noemie DA COSTA

CONTACT

+33 9 72 57 61 60 ndacosta@getaid.org

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394

Inflammatory Bowel Disease (IBD)Crohn Disease (CD)+2 more

View study

RECRUITING

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420

IBD (Inflammatory Bowel Disease)IBS - Irritable Bowel Syndrome+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 18, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease

Inclusion Criteria

Exclusion Criteria

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Assessment and Educational Intervention to Reduce Ultra-processed Food Consumption in Pediatric Patients With IBD

Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease

Assessing Interventions of Diet in IBD